DRUG · Unmapped registry intervention
eftilagimod alpha
Find medicine records ·
Find other trials using this name
Clinical trial
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
NCT03625323
Study summary
ClinicalTrials.govCombination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
pembrolizumab (KEYTRUDA®)
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Interventions
Sponsors & collaborators
Immutep S.A.S.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03625323 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.